Eidos Therapeutics Inc
(EIDX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -25,786 | -11,733 | -40,725 | -30,871 | -20,257 |
| Depreciation Amortization | 33 | 15 | 1,067 | 88 | 1,035 |
| Accounts payable and accrued liabilities | -114 | 1,256 | 1,390 | 1,852 | 1,157 |
| Other Working Capital | -2,516 | 648 | 666 | 1,256 | 259 |
| Other Operating Activity | 2,251 | -294 | 4,301 | 3,970 | 3,008 |
| Operating Cash Flow | $-26,132 | $-10,108 | $-33,301 | $-23,705 | $-14,798 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -35 | N/A | -150 | -144 | -129 |
| Investing Cash Flow | $-35 | $N/A | $-150 | $-144 | $-129 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | 10,000 | 10,000 | 10,000 |
| Common Stock Issued | 420 | 25 | 111,226 | 111,045 | 112,244 |
| Other Financing Activity | 0 | 0 | 63,875 | 63,875 | 63,875 |
| Financing Cash Flow | $420 | $25 | $185,101 | $184,920 | $186,119 |
| Beginning Cash Position | 157,147 | 157,147 | 5,497 | 5,497 | 5,497 |
| End Cash Position | 131,400 | 147,064 | 157,147 | 166,568 | 176,689 |
| Net Cash Flow | $-25,747 | $-10,083 | $151,650 | $161,071 | $171,192 |
| Free Cash Flow | |||||
| Operating Cash Flow | -26,132 | -10,108 | -33,301 | -23,705 | -14,798 |
| Capital Expenditure | -35 | N/A | -150 | -144 | -129 |
| Free Cash Flow | -26,167 | -10,108 | -33,451 | -23,849 | -14,927 |